This compilation opens with a review of the current knowledge regarding the impact of endocrine disruptors on human health, as well as the mechanisms contributing to it. The authors emphasize the evidence of aquaporin modulation by hypoxia and erythropoietin, as these water channels are increasingly valued as potential biomarkers of disease, as well as pharmacological targets for the treatment of brain and renal injuries, cardiovascular disorders and cancer. Later, the safety and tolerability of adalimumab demonstrated in pivotal phase III clinical trials is examined, along with long-term follow up data from open-label extensions and the ESPRIT registry. Adalimumab for the treatment of ankylosing spondylitis and peripheral spondyloarthritis is also discussed. The authors go on to study the types, causes, effect and problems related to polycystic ovary syndrome. The closing study deals with the relationship between reactive oxygen species and male fertility, providing some futuristic approaches for better research in the field.
